Cuide de suas artérias!

Não somente o colesterol ruim (LDL colesterol) está envolvido na formação de placas de gorduras. 

Sabemos que diabetes, hipertensão, obesidade, tabagismo, excesso de álcool AUMENTAM O RISCO CARDIOVASCULAR. Mas o que essas doenças ou estados tem em comum? 

Estresse oxidativo é o fator comum de todos essas doenças e diversas como: câncer, doenças degenerativas, doenças auto-imunes e talvez todas as patologias.

Atualmente TODOS OS FATORES que agravam o estado de estresse oxidativo, balanço negativo entre  produção de  antioxidantes versus produção de radicais livres contribuem direta ou indiretamente para a formação das placas pois atuam gerando inflamação no nosso endotélio (camada que reveste internamente nossas artérias considerado recentemente o maior órgão do corpo humano). 

Então: 

1)    Carências de vitaminas, minerais, nutrientes

a.     Vitamina C

b.     Vitamina D

c.      Vitamina K

d.     Omega 3 (EPA e DHA)

e.     Minerais como zinco, selênio, magnésio, manganês

2)    Metais pesados em quantidade elevada

3)    Inflamação vascular  presente, podemos avaliar por diversos exames simples

a.     Proteina C reativa 

b.     Homocisteína

c.     Fibrinogênio

d.     Lipoproteina A

4)    Glicose no sangue ou insulina aumentada, associados ou não a diabetes

5)    Incapacidade de síntese de óxido nítrico, substância produzida no endotélio. Quando este está inflamado diminui sua síntese auxiliando no desenvolvimento de hipertensão arterial 

6)    Excesso de estrogênios em homens aliado a baixo nível de testosterona livre diminui a elasticidade das artérias tornando-as mais rígidas

7)    Baixa de estradiol (tipo de estrogênio) em mulheres. Por isso a menopausa deve ser tratada com um estado potencial ruim para a parte cardiovascular das mulheres. 

Procure uma avaliação médica preventiva para mudar esse quadro, independente da sua genética ser boa ou ruim para doenças. 

“Invista tempo  agora para conquistar saúde, do contrário no futuro gastará tempo para tratar doenças.”

Dr . Marcos Vilar

References 

Bentzon, J.F.; Otsuka, F.; Virmani, R.; Falk, E. Mechanisms of plaque formation and rupture. Circ. Res. 2014, 114, 1852–1866. 

Chen, Q.; Wang, Q.; Zhu, J.; Xiao, Q.; Zhang, L. Reactive oxygen species: Key regulators in vascular health and diseases. Br. J. Pharmacol. 2017. 

Montezano, A.C.; Dulak-Lis, M.; Tsiropoulou, S.; Harvey, A.; Briones, A.M.; Touyz, R.M. Oxidative stress and human hypertension: Vascular mechanisms, biomarkers, and novel therapies. Can. J. Cardiol. 2015, 31, 631–641. 

Konior, A.; Schramm, A.; Czesnikiewicz-Guzik, M.; Guzik, T.J. NADPH oxidases in vascular pathology. Antioxid. Redox Signal. 2014, 20, 2794–2814. 

Violi, F.; Pignatelli, P. Clinical Application of NOX Activity and Other Oxidative Biomarkers in Cardiovascular Disease: A Critical Review. Antioxid. Redox Signal. 2015, 23, 514–532. 

Violi, F.; Carnevale, R.; Loffredo, L.; Pignatelli, P.; Gallin, J.I. NADPH Oxidase-2 and Atherothrombosis: Insight from Chronic Granulomatous Disease. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 218–225. 

Violi, F.; Loffredo, L.; Carnevale, R.; Pignatelli, P.; Pastori, D. Atherothrombosis and oxidative stress: Mechanisms and management in elderly. Antioxid. Redox Signal. 2017. 

Steinberg, D. The LDL modification hypothesis of atherogenesis: An update. J. Lipid Res. 2009, 50, S376–S381. 

Michel, J.B.; Martin-Ventura, J.L.; Nicoletti, A.; Ho-Tin-Noé, B. Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis 2014, 234, 311–319. 

Michel, J.B.; Martin-Ventura, J.L.; Egido, J.; Sakalihasan, N.; Treska, V.; Lindholt, J.; Allaire, E.; Thorsteinsdottir, U.; Cockerill, G.; Swedenborg, J. FAD EU consortium. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc. Res. 2011, 90, 18–27. 

Farbstein, D.; Soloveichik, Y.Z.; Levy, N.S.; Levy, A.P. Genetics of redox systems and their relationship with cardiovascular disease. Curr. Atheroscler. Rep. 2011, 13, 215–224. 

Dröge, W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82, 47–95. 

Garcia-Redondo, A.B.; Aguado, A.; Briones, A.M.; Salaices, M. NADPH oxidases and vascular remodeling in cardiovascular diseases. Pharmacol. Res. 2016, 114, 110–120. 

Holmström, K.M.; Finkel, T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 2014, 15, 411–421. 

Drummond, G.R.; Selemidis, S.; Griendling, K.K.; Sobey, C.G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 2011, 10, 453–471. 

Rodríguez, C.; Martínez-González, J.; Raposo, B.; Alcudia, J.F.; Guadall, A.; Badimon, L. Regulation of lysyl oxidase in vascular cells: Lysyl oxidase as a new player in cardiovascular diseases. Cardiovasc. Res. 2008, 79, 7–13. 

Lu, J.; Holmgren, A. The thioredoxin antioxidant system. Free Radic. Biol. Med. 2014, 66, 75–87. 

Frijhoff, J.; Winyard, P.G.; Zarkovic, N.; Davies, S.S.; Stocker, R.; Cheng, D.; Knight, A.R.; Taylor, E.L.; Oettrich, J.; Ruskovska, T.; et al. Clinical Relevance of Biomarkers of Oxidative Stress. Antioxid. Redox Signal. 2015, 23, 1144–1170. 

Chen, B.; Lu, Y.; Chen, Y.; Cheng, J. The role of Nrf2 in oxidative stress-induced endothelial injuries. J. Endocrinol. 2015, 225, R83–R99. 

Egea, J.; Fabregat, I.; Frapart, Y.M.; Ghezzi, P.; Görlach, A.; Kietzmann, T.; Kubaichuk, K.; Knaus, U.G.; Lopez, M.G.; Olaso-Gonzalez, G.; et al. European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol. 2017, 13, 94–162. 

McCormick, M.L.; Gavrila, D.; Weintraub, N.L. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 461–469. 

Emeto, T.I.; Moxon, J.V.; Au, M.; Golledge, J. Oxidative stress and abdominal aortic aneurysm: Potential treatment targets. Clin. Sci. (Lond.) 2016, 130, 301–315. 

Förstermann, U.; Xia, N.; Li, H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circ. Res. 2017, 120, 713–735. 

Kattoor, A.J.; Pothineni, N.V.K.; Palagiri, D.; Mehta, J.L. Oxidative Stress in Atherosclerosis. Curr. Atheroscler. Rep. 2017, 19, 42. 

Nosalski, R.; Guzik, T.J. Perivascular adipose tissue inflammation in vascular disease. Br. J. Pharmacol. 2017, 174, 3496–3513. 

Lassègue, B.; San Martín, A.; Griendling, K.K. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ. Res. 2012, 110, 1364–1390. 

Schröder, K. NADPH oxidases in redox regulation of cell adhesion and migration. Antioxid. Redox Signal. 2014, 20, 2043–2058. 

Montezano, A.C.; Touyz, R.M. Reactive oxygen species, vascular Noxs, and hypertension: Focus on translational and clinical research. Antioxid. Redox Signal. 2014, 20, 164–182. 

Guzik, T.J.; West, N.E.; Black, E.; McDonald, D.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ. Res. 2000, 86, E85–E90. 

Kalinina, N.; Agrotis, A.; Tararak, E.; Antropova, Y.; Kanellakis, P.; Ilyinskaya, O.; Quinn, M.T.; Smirnov, V.; Bobik, A. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 2037–2043. 

Sorescu, D.; Weiss, D.; Lassègue, B.; Clempus, R.E.; Szocs, K.; Sorescu, G.P.; Valppu, L.; Quinn, M.T.; Lambeth, J.D.; Vega, J.D.; et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002, 105, 1429–1435. 

Azumi, H.; Inoue, N.; Takeshita, S.; Rikitake, Y.; Kawashima, S.; Hayashi, Y.; Itoh, H.; Yokoyama, M. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 1999, 100, 1494–1498. 

Gray, S.P.; Di Marco, E.; Kennedy, K.; Chew, P.; Okabe, J.; El-Osta, A.; Calkin, A.C.; Biessen, E.A.; Touyz, R.M.; Cooper, M.E.; et al. Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 295–307. 

Guzik, T.J.; Chen, W.; Gongora, M.C.; Guzik, B.; Lob, H.E.; Mangalat, D.; Hoch, N.; Dikalov, S.; Rudzinski, P.; Kapelak, B.; et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J. Am. Coll. Cardiol. 2008, 52, 1803–1909. 

Manea, A.; Manea, S.A.; Gan, A.M.; Constantin, A.; Fenyo, I.M.; Raicu, M.; Muresian, H.; Simionescu, M. Human monocytes and macrophages express NADPH oxidase 5; a potential source of reactive oxygen species in atherosclerosis. Biochem. Biophys. Res. Commun. 2015, 461, 172–179. 

Guzik, T.J.; Mussa, S.; Gastaldi, D.; Sadowski, J.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105, 1656–1662. 

Zalba, G.; Beloqui, O.; San José, G.; Moreno, M.U.; Fortuño, A.; Díez, J. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1452–1457. 

Guzik, B.; Sagan, A.; Ludew, D.; Mrowiecki, W.; Chwała, M.; Bujak-Gizycka, B.; Filip, G.; Grudzien, G.; Kapelak, B.; Zmudka, K.; et al. Mechanisms of oxidative stress in human aortic aneurysms—Association with clinical risk factors for atherosclerosis and disease severity. Int. J. Cardiol. 2013, 168, 2389–2396. 

Loffredo, L.; Carnevale, R.; Sanguigni, V.; Plebani, A.; Rossi, P.; Pignata, C.; De Mattia, D.; Finocchi, A.; Martire, B.; Pietrogrande, M.C.; et al. Does NADPH oxidase deficiency cause artery dilatation in humans? Antioxid. Redox Signal. 2013, 18, 1491–1496. 

Violi, F.; Pignatelli, P.; Pignata, C.; Plebani, A.; Rossi, P.; Sanguigni, V.; Carnevale, R.; Soresina, A.; Finocchi, A.; Cirillo, E.; et al. Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 406–412. 

Sibley, C.T.; Estwick, T.; Zavodni, A.; Huang, C.Y.; Kwan, A.C.; Soule, B.P.; Long Priel, D.A.; Remaley, A.T.; Rudman Spergel, A.K.; Turkbey, E.B.; et al. Assessment of atherosclerosis in chronic granulomatous disease. Circulation 2014, 130, 2031–2039. 

Guzik, T.J.; West, N.E.; Black, E.; McDonald, D.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000, 102, 1744–1747. 

Arca, M.; Conti, B.; Montali, A.; Pignatelli, P.; Campagna, F.; Barillà, F.; Tanzilli, G.; Verna, R.; Vestri, A.; Gaudio, C.; Violi, F. C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 752–757. 

Galijasevic, S.; Maitra, D.; Lu, T.; Sliskovic, I.; Abdulhamid, I.; Abu-Soud, H.M. Myeloperoxidase interaction with peroxynitrite: Chloride deficiency and heme depletion. Free Radic. Biol. Med. 2009, 47, 431–439. 

Shao, B.; Tang, C.; Heinecke, J.W.; Oram, J.F. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J. Lipid Res. 2010, 51, 1849–1858. 

Eiserich, J.P.; Baldus, S.; Brennan, M.L.; Ma, W.; Zhang, C.; Tousson, A.; Castro, L.; Lusis, A.J.; Nauseef, W.M.; White, C.R.; et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002, 296, 2391–2394. 

Daugherty, A.; Dunn, J.L.; Rateri, D.L.; Heinecke, J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Investig. 1994, 94, 437–444. 

Khine, H.W.; Teiber, J.F.; Haley, R.W.; Khera, A.; Ayers, C.R.; Rohatgi, A. Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study. Atherosclerosis 2017, 263, 156–162. 

Stadler, N.; Lindner, R.A.; Davies, M.J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: Evidence for the presence of elevated levels of iron and copper. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 949–954. 

Delbosc, S.; Bayles, R.G.; Laschet, J.; Ollivier, V.; Ho-Tin-Noé, B.; Touat, Z.; Deschildre, C.; Morvan, M.; Louedec, L.; Gouya, L.; et al. Erythrocyte Efferocytosis by the Arterial Wall Promotes Oxidation in Early-Stage Atheroma in Humans. Front. Cardiovasc. Med. 2017, 4, 43. 

Nagy, E.; Eaton, J.W.; Jeney, V.; Soares, M.P.; Varga, Z.; Galajda, Z.; Szentmiklósi, J.; Méhes, G.; Csonka, T.; Smith, A.; et al. Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1347–1353. 

Kraml, P. The role of iron in the pathogenesis of atherosclerosis. Physiol. Res. 2017, 66 (Suppl. 1), S55–S67. 

Sawada, H.; Hao, H.; Naito, Y.; Oboshi, M.; Hirotani, S.; Mitsuno, M.; Miyamoto, Y.; Hirota, S.; Masuyama, T. Aortic iron overload with oxidative stress and inflammation in human and murine abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 1507–1514. 

Sullivan, J.L. Iron and sex difference in heart disease risk. Lancet 1981, 1, 1293–1294. 

Martinez-Pinna, R.; Lindholt, J.S.; Madrigal-Matute, J.; Blanco-Colio, L.M.; Esteban-Salan, M.; Torres-Fonseca, M.M.; Lefebvre, T.; Delbosc, S.; Laustsen, J.; Driss, F.; et al. From tissue iron retention to low systemic haemoglobin levels, new pathophysiological biomarkers of human abdominal aortic aneurysm. 

Griendling, K.K.; Touyz, R.M.; Zweier, J.L.; Dikalov, S.; Chilian, W.; Chen, Y.R.; Harrison, D.G.; Bhatnagar, A. American Heart Association Council on Basic Cardiovascular Sciences. Measurement of Reactive Oxygen Species, Reactive Nitrogen Species, and Redox-Dependent Signaling in the Cardiovascular System: A Scientific Statement from the American Heart Association. Circ. Res. 2016, 119, 39–75. 

Parthasarathy, S.; Steinberg, D.; Witztum, J.L. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu. Rev. Med. 1992, 43, 219–225. 

Ball, R.Y.; Bindman, J.P.; Carpenter, K.L.; Mitchinson, M.J. Oxidized low density lipoprotein induces ceroid accumulation by murine peritoneal macrophages in vitro. Atherosclerosis 1986, 60, 173–181. 

Glavind, J.; Hartmann, S. The occurrence of peroxidized lipids in atheromatous human aortas. Experientia 1951, 7, 464. 

Ylä-Herttuala, S.; Palinski, W.; Rosenfeld, M.E.; Parthasarathy, S.; Carew, T.E.; Butler, S.; Witztum, J.L.; Steinberg, D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Investig. 1989, 84, 1086–1095. 

Malle, E.; Marsche, G.; Arnhold, J.; Davies, M.J. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim. Biophys. Acta. 2006, 1761, 392–415. 

Kotani, K.; Maekawa, M.; Kanno, T.; Kondo, A.; Toda, N.; Manabe, M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim. Biophys. Acta 1994, 1215, 121–125. 

Fogelman, A.M.; Shechter, I.; Seager, J.; Hokom, M.; Child, J.S.; Edwards, P.A. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl. Acad. Sci. USA 1980, 77, 2214–2218. 

Toshima, S.; Hasegawa, A.; Kurabayashi, M.; Itabe, H.; Takano, T.; Sugano, J.; Shimamura, K.; Kimura, J.; Michishita, I.; Suzuki, T.; et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2243–2247. 

Tanaga, K.; Bujo, H.; Inoue, M.; Mikami, K.; Kotani, K.; Takahashi, K.; Kanno, T.; Saito, Y. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 662–666. 

Kotani, K.; Tashiro, J.; Yamazaki, K.; Nakamura, Y.; Miyazaki, A.; Bujo, H.; Saito, Y.; Kanno, T.; Maekawa, M. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus. Clin. Chim. Acta 2015, 450, 145–150. 

Amaki, T.; Suzuki, T.; Nakamura, F.; Hayashi, D.; Imai, Y.; Morita, H.; Fukino, K.; Nojiri, T.; Kitano, S.; Hibi, N.; et al. Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease. Heart 2004, 90, 1211–1213. 

Matsuo, Y.; Kubo, T.; Okumoto, Y.; Ishibashi, K.; Komukai, K.; Tanimoto, T.; Ino, Y.; Kitabata, H.; Hirata, K.; Imanishi, T.; et al. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease. Eur. Heart J. Cardiovasc. Imaging 2013, 14, 43–50. 

Ito, T.; Fujita, H.; Tani, T.; Ohte, N. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent. Atherosclerosis 2015, 239, 311–317. 

Gounopoulos, P.; Merki, E.; Hansen, L.F.; Choi, S.H.; Tsimikas, S. Antibodies to oxidized low density lipoprotein: Epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol. 2007, 55, 821–837. 

Ravandi, A.; Boekholdt, S.M.; Mallat, Z.; Talmud, P.J.; Kastelein, J.J.; Wareham, N.J.; Miller, E.R.; Benessiano, J.; Tedgui, A.; Witztum, J.L.; et al. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: Results from the EPIC-Norfolk Study. J. Lipid Res. 2011, 52, 1829–1836. 

Tsimikas, S.; Willeit, P.; Willeit, J.; Santer, P.; Mayr, M.; Xu, Q.; Mayr, A.; Witztum, J.L.; Kiechl, S. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J. Am. Coll. Cardiol. 2012, 60, 2218–2229. 

Bowry, V.W.; Stanley, K.K.; Stocker, R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA 1992, 89, 10316–10320. 

Murphy, A.J.; Woollard, K.J. High-density lipoprotein: A potent inhibitor of inflammation. Clin. Exp. Pharmacol. Physiol. 2010, 37, 710–718. 

Mineo, C.; Deguchi, H.; Griffin, J.H.; Shaul, P.W. Endothelial and antithrombotic actions of HDL. Circ. Res. 2006, 98, 1352–1364. 

Gordon, D.J.; Probstfield, J.L.; Garrison, R.J.; Neaton, J.D.; Castelli, W.P.; Knoke, J.D.; Jacobs, D.R., Jr.; Bangdiwala, S.; Tyroler, H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79, 8–15. 

Golledge, J.; van Bockxmeer, F.; Jamrozik, K.; McCann, M.; Norman, P.E. Association between serum lipoproteins and abdominal aortic aneurysm. Am. J. Cardiol. 2010, 105, 1480–1484. 

Stather, P.W.; Sidloff, D.A.; Dattani, N.; Gokani, V.J.; Choke, E.; Sayers, R.D.; Bown, M.J. Meta-analysis and meta-regression analysis of biomarkers for abdominal aortic aneurysm. Br. J. Surg. 2014, 101, 1358–1372. 

Burillo, E.; Lindholt, J.S.; Molina-Sánchez, P.; Jorge, I.; Martinez-Pinna, R.; Blanco-Colio, L.M.; Tarin, C.; Torres-Fonseca, M.M.; Esteban, M.; Laustsen, J.; et al. ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression. Thromb. Haemost. 2015, 113, 1335–1346. 

Burillo, E.; Andres, E.M.; Mateo-Gallego, R.; Fiddyment, S.; Jarauta, E.; Cenarro, A.; Civeira, F. High-density lipoprotein cholesterol increase and non-cardiovascular mortality: A meta-analysis. Heart 2010, 96, 1345–1351. 

Karathanasis, S.K.; Freeman, L.A.; Gordon, S.M.; Remaley, A.T. The Changing Face of HDL and the Best Way to Measure It. Clin. Chem. 2017, 63, 196–210. 

Khera, A.V.; Cuchel, M.; de la Llera-Moya, M.; Rodrigues, A.; Burke, M.F.; Jafri, K.; French, B.C.; Phillips, J.A.; Mucksavage, M.L.; Wilensky, R.L.; et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 2011, 364, 127–135. 

Rohatgi, A.; Khera, A.; Berry, J.D.; Givens, E.G.; Ayers, C.R.; Wedin, K.E.; Neeland, I.J.; Yuhanna, I.S.; Rader, D.R.; de Lemos, J.A.; et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 2014, 371, 2383–2393. 

O’Reilly,M.;Dillon,E.;Guo,W.;Finucane,O.;McMorrow,A.;Murphy,A.;Lyons,C.;Jones,D.;Ryan,M.; Gibney, M.; et al. High-Density Lipoprotein Proteomic Composition, and not Efflux Capacity, Reflects Differential Modulation of Reverse Cholesterol Transport by Saturated and Monounsaturated Fat Diets. Circulation 2016, 133, 1838–1850.